0 Commentaires
0 Parts
268 Vue
0 Aperçu
Rechercher
Découvrez de nouvelles personnes, créer de nouvelles connexions et faire de nouveaux amis
-
Connectez-vous pour aimer, partager et commenter!
-
The Strategic Outsourcing: How Contract Manufacturing for Biologics Is Driving Drug DevelopmentThe development and manufacturing of biologic drugs is a complex and capital-intensive endeavor. Contract manufacturing for biologics , particularly for fill-finish services, has emerged as a strategic solution for pharmaceutical companies of all sizes. The global biologics fill-finish services market, valued at USD 9.3 billion in 2025 and projected to grow to USD 15.0 billion by...0 Commentaires 0 Parts 254 Vue 0 Aperçu
-
Global Biopharmaceutical and Bio-CDMO Market Growing at 14.2% CAGR Through 2032According to a new report from Intel Market Research, the global Biopharmaceutical and Bio-CDMO market was valued at USD 25.71 billion in 2024 and is projected to grow from USD 28.95 billion in 2025 to USD 63.88 billion by 2032, exhibiting a robust CAGR of 14.2% during the forecast period (2025–2032). This growth is driven by increasing demand for biologics and biosimilars due to their...0 Commentaires 0 Parts 1KB Vue 0 Aperçu
-
Global Microbial Fermentation APIs Market Growing at 1.5% CAGR Through 2032According to a new report from Intel Market Research, the global Microbial Fermentation APIs market was valued at USD 27.57 billion in 2024 and is projected to reach USD 30.56 billion by 2032, exhibiting a steady CAGR of 1.5% during the forecast period (2025–2032). This growth is driven by the increasing demand for antibiotics, amino acids, and vitamins, particularly in emerging economies...0 Commentaires 0 Parts 1KB Vue 0 Aperçu
-
United States Sterile Fill-Finish for Cell and Gene Therapies Market Growing at 8.9%According to a new report from Intel Market Research, the United States Sterile Fill-Finish for Cell and Gene Therapies Market was valued at USD 0.54 billion in 2025 and is projected to reach USD 1.04 billion by 2034, growing at a robust CAGR of 8.9% during the forecast period (2025–2034). This expansion is driven by accelerating investments in cell‑and‑gene therapy pipelines, supportive...0 Commentaires 0 Parts 1KB Vue 0 Aperçu